Harrow, Inc. announced that it has partnered with three leading healthcare technology platforms to expand U.S. availability of VEVYE (cyclosporine ophthalmic solution) 0.1%, a patented, non-preserved, twice-daily (BID) dosed, ophthalmic solution prescription drug based on a ?water-free? semifluorinated alkane eyedrop technology. VEVYE, uniquely dispensed in a 10 microliter drop, is the first and only cyclosporine-based product indicated for treating both signs and symptoms of dry eye disease.

Harrow?s three market access partnerships for VEVYE include: PhilRx is aninnovative patient access platformthatprovides end-to-end visibility into the entire prescription life cycle, starting when the eyecare professional (ECP) writes a VEVYE prescription electronically to PhilRx directly from their electronic health record (EHR). Using the PhilRx platform simplifies the prior authorization process (PA) for physicians by providing one-click submission of PAs, streamlining the insurance coverage process for patients, and increasing the chances of insurance reimbursement. PhilRx offers a variety of patient benefits, including best price, fast free shipping, text refill reminders, and best-in-class customer service.

Apollo Care is a comprehensive program designed to establish and manage copay program deployment, optimizing patient access and affordability of VEVYE. PARx Solutionsis a web-based technology stack that helps prescribers ? free of charge ?

overcome cumbersome, frustrating, and time-consuming challenges resulting from prior authorizations, thus ensuring that patients get the medication prescribed.